Virax Biolabs Group Limited(VRAX)Earnings, Financials & Key Ratios
VRAX•NASDAQ
$0.14
Price updated Jun 25, 2026
AboutVirax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.Show more
- Revenue$6K-96.0%
- EBITDA-$6M+9.0%
- Net Income-$6M+10.0%
- EPS (Diluted)-1.95+42.0%
- Gross Margin-838.21%-2691.7%
- EBITDA Margin-91920.87%-2148.9%
- Operating Margin-97344.76%-2243.8%
- Net Margin-95739.17%-2124.0%
- ROE-114.35%-19.2%
VRAX Price & Volume
Virax Biolabs Group Limited (VRAX) stock price & volume — 10-year historical chart
Loading chart...
Virax Biolabs Faces Severe Operational Revenue Collapse
Investment Thesis • Updated 2026Q2
VerdictNegative: The company's inability to generate positive cash flow
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Existential liquidity and solvency
"Virax Biolabs exhibits a deteriorating financial profile characterized by a 95.95% year-over-year revenue decline and persistent negative margins that suggest the core business model is currently non-viable. The company's reliance on stock-based compensation and rapid cash depletion, evidenced by a $3.3M cash balance down from $9.4M in 2023Q4, indicates significant solvency risks. Investors should remain cautious as the firm struggles to transition its immunology platform while maintaining an unsustainable cost structure that lacks alignment with its negligible commercial output."
Verdict Logic
highlighted by a 2026Q2 free cash flow of -$3.1M, suggests an existential liquidity risk that outweighs any potential upside from its speculative biotech pivot.
VRAX Growth Metrics
Virax Biolabs Group Limited (VRAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-42.4%
3 Years-
TTM1225.81%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-28.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM40.59%
Return on Capital
10 Years-117.16%
5 Years-117.16%
3 Years-117.16%
Last Year-111.36%
Peers Comparison
Key metrics vs top competitors for Virax Biolabs Group Limited (VRAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.14 | $586.16K | -0.07 | -95.95% | -95739.17% | -114.35% | — | |
| $3.05 | $3.4M | -0.09 | -84.1% | -6753.69% | -164.92% | — | |
| $13.52 | $920.47M | -0.81 | -1.89% | -45.57% | -56.31% | — | |
| $19.44 | $552.11M | -9.87 | 13.83% | -23.04% | -6.74% | — | |
| $1.12 | $3.68M | -0.23 | -7.37% | -109.95% | -71.38% | — | |
| $554.94 | $44.08B | 42.43 | 10.42% | 24.63% | 70.87% | — |
Compare VRAX vs Peers
Virax Biolabs Group Limited (VRAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when VRAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VRAX Frequently Asked Questions
Virax Biolabs Group Limited (VRAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Virax Biolabs Group Limited's revenue?
Virax Biolabs Group Limited (VRAX) reported $0.1M in revenue for fiscal year 2025. This represents a 12% decrease from $0.1M in 2020.
How fast is Virax Biolabs Group Limited growing?
Virax Biolabs Group Limited (VRAX) saw revenue decline by 96.0% over the past year.
Is VRAX profitable?
Virax Biolabs Group Limited (VRAX) reported a net loss of $12.2M for fiscal year 2025.
Dividend & Returns
What is VRAX's return on equity?
Virax Biolabs Group Limited (VRAX) has a return on equity (ROE) of -114.4%. Negative ROE indicates the company is unprofitable.
What is Virax Biolabs Group Limited's free cash flow?
Virax Biolabs Group Limited (VRAX) had negative free cash flow of $11.5M in fiscal year 2025, likely due to heavy capital investments.